RET Alterations in NSCLC and Thyroid Cancer: From Molecular Testing to Treatment Selection

CME: 0.75

August 12, 2022
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This activity is intended for oncologists and pathologists who care for/manage patients with NSCLC and thyroid cancer.

Program Overview

New genetic markers and targeted therapies are driving a rapidly evolving landscape in cancer care. Are you ready to test for these markers and select appropriate treatment options? Learn about RET alterations in lung cancer and thyroid cancer from experts Dr. Justin Gainor and Dr. Marcia Brose as they present recent evidence and guideline recommendations. Hear patient cases and excerpts from their live discussions. Join your colleagues in this new frontier of personalized medicine, and find out why they say, “Right now, I’m building practice habits. This activity helped set a foundation for becoming an attending in a few months.”

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Introduce improved models for early and effective biomarker testing
  • Identify appropriate patients and optimize treatment for RET targeted therapy
  • Develop strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer

Post a comment to this article